Lilly's stock leads S&P 500 losers as Mounjaro, Zepbound sales to miss forecasts
Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter revenue guidance that was below Wall Street expectations,
Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.
I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...
24/7 Wall St. on MSN2h
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...
The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...
To approve the generic version of Mounjaro or Zepbound, the FDA will need clear evidence that tirzepatide works as well as the branded medication. Zepbound, which contains the active ingredient ...
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...
J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback